New bivalent polio vaccine playing key role in global polio eradication

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial

A child is immunized in Jalalabad, eastern Afghanistan on a memorable day for polio eradication: 16 December 2009, the first day the groundbreaking bivalent oral polio vaccine was ever used. Cornelia Walther/UNICEF

A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3)  vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.

For details, please go to:
http://www.thelancet.com


Related News

   18/01/2022
Soni Farhan’s work to eradicate polio has been as healing for her as it has been for the children she’s determined to help.
   13/01/2022
Update on polio eradication efforts in Pakistan for December 2021
   21/12/2021
Update on polio eradication efforts in Pakistan for November 2021
   20/12/2021
2021 may go down in history as the turning point in the global effort to eradicate polio.
   16/12/2021
High level commitment to ending polio in Pakistan by regional UN leadership
   01/12/2021
Update on polio eradication efforts in Pakistan for October 2021